Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

• Ian N Bruce,
• Sarowar Golam,
• Jason Steenkamp,
• Pearl Wang,
• Evelyn Worthington,
• Barnabas Desta,
• Konstantina Psachoulia,
• Wilma Erhardt,
• Raj Tummala

Affiliations

Ian N Bruce

ORCiD

Division of Musculoskeletal & Dermatological Sciences, Centre for Epidemiology Versus Arthritis, The University of Manchester & NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

Sarowar Golam

Global Market Access & Pricing, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Jason Steenkamp

EVERSANA™, Burlington, ON, L7N 3H8, Canada

Pearl Wang

EVERSANA™, Burlington, ON, L7N 3H8, Canada

Evelyn Worthington

EVERSANA™, Burlington, ON, L7N 3H8, Canada

Barnabas Desta

BioPharmaceuticals Business Unit, AstraZeneca, Gaithersburg, MD 20878, USA

Konstantina Psachoulia

Respiratory, Inflammation & Autoimmunity, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA

Wilma Erhardt

Global Market Access & Pricing, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Raj Tummala

Respiratory, Inflammation & Autoimmunity, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA